NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
17/03/2026
Voltar para busca
Dado oficial do USPTO
PHARMACORD
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PHARMACORD
ST13
US500000087236919Classe
35, 36, 41, 42, 44, 45
Pedido
87236919
Registro
5782112
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
18/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 36, 41, 42, 44, 45
Data de depósito
15/11/2016
Data de registro
18/06/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/03/2026
Última transação
18/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/10/2018
Primeiro uso no comércio
01/10/2018
Código do desenho
4
Tipo de titular
16
Localização do titular
Louisville, KY, US
Examinador
COGAN, BRITTNEY LORRAINE
Localização atual
Historical data usage
Titulares e representantes
Titulares
PharmaCord LLC
Representantes
Trevor T. Graves STITES & HARBISON PLLC
Classificação técnica
Classes Nice
Classe 35Classe 36Classe 41Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Market analysis services in the field of specialty drug commercialization; Business consulting services relating to product distribution and operations management in the field of new specialty drugs; Patient relationship management services; Business consulting services relating to the operation of quick start and interim care programs; Management services provided to pharmaceutical manufacturers for controlling drug inventories; Healthcare business administration servicesadministering patient reimbursement programs and administering pharmacy reimbursement programs; Business management in the field of patient assistance programsprescription drugs and new specialty drugs
Classe 36
Claims administration services in the field of health insuranceadministration and coordination of healthcare assignment of benefits for others and verification of patient eligibility for health- and prescription-benefits coverage of pharmaceuticals; Financial administration of patient reimbursement programs; Financial management of reimbursement payments for others
Classe 41
Educational servicesconducting programs in the fields of drug therapyside effect managementlifestyle managementdisease state management and proper administration of medication; Educational servicesproviding clinical support programs regarding drug therapyside effect managementdisease state management and proper administration of medication
Classe 42
Data warehousing services; Database development servicescollecting and maintaining patient information and registry data; Database development servicescustomized data collection and maintaining related databases in the field of prescription drugs; Software as a service (SAAS) serviceshosting software for use by others for the purpose of connecting clinical programs with specialty drug manufacturersmanaging inventorybilling and account receivablesas well as shipping and reportingmaster patient data aggregation and analysiscall center services; Developing customized software for others for the purpose of connecting clinical programs with specialty drug manufacturersmanaging inventorybilling and account receivablesas well as managing shipping and reportingmaster patient data aggregation and analysiscall center services
Classe 44
Medical counseling in the field of drug therapyside effect managementdisease state management and proper administration of medication; Pharmaceutical consultation in the field of new specialty drugs; Providing information to patients in the field of administering medications; Providing medical information to patients; Patient health care counseling and advice regarding products in the field of prescription drugs; Providing information in the field of prescription drugs distributed via the Internet
Classe 45
Personal lifestyle consulting services; Providing patient advocate and case management servicescoordinating the procurement and administration of medication; Providing emotional counseling and emotional support services for medical patients
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
17/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/03/2026
E815
TEAS SECTION 8 & 15 RECEIVED
15/12/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
19/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
19/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/07/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/07/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/07/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/07/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/07/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/06/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
18/06/2019
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
14/05/2019
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
13/05/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/04/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
29/04/2019
EX3G
SOU EXTENSION 3 GRANTED
29/04/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
29/04/2019
IUAF
USE AMENDMENT FILED
23/04/2019
EXT3
SOU EXTENSION 3 FILED
23/04/2019
EEXT
SOU TEAS EXTENSION RECEIVED
23/04/2019
EISU
TEAS STATEMENT OF USE RECEIVED
23/04/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/10/2018
EX2G
SOU EXTENSION 2 GRANTED
23/10/2018
EXT2
SOU EXTENSION 2 FILED
23/10/2018
EEXT
SOU TEAS EXTENSION RECEIVED
23/10/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26/04/2018
EX1G
SOU EXTENSION 1 GRANTED
24/04/2018
EXT1
SOU EXTENSION 1 FILED
24/04/2018
EEXT
SOU TEAS EXTENSION RECEIVED
24/04/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
24/10/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/08/2017
PUBO
PUBLISHED FOR OPPOSITION
29/08/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/07/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
21/07/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
21/07/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
21/07/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/07/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/07/2017
GNFR
FINAL REFUSAL E-MAILED
05/07/2017
CNFR
FINAL REFUSAL WRITTEN
05/07/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/06/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
16/06/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/06/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/06/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/05/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/05/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/02/2017
GNRT
NON-FINAL ACTION E-MAILED
22/02/2017
CNRT
NON-FINAL ACTION WRITTEN
22/02/2017
DOCK
ASSIGNED TO EXAMINER
22/02/2017
MPMK
NOTICE OF PSEUDO MARK E-MAILED
22/11/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/11/2016
NWAP
NEW APPLICATION ENTERED
18/11/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PHARMACORD ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.